Cargando…
Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review
Since December 2019, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there...
Autores principales: | Grange, Lucile, Guilpain, Philippe, Truchetet, Marie-Elise, Cracowski, Jean-Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320663/ https://www.ncbi.nlm.nih.gov/pubmed/32665090 http://dx.doi.org/10.1016/j.therap.2020.06.013 |
Ejemplares similares
-
Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases
por: Richez, Christophe, et al.
Publicado: (2020) -
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
por: Kostine, Marie, et al.
Publicado: (2019) -
Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic
por: Cracowski, Jean-Luc, et al.
Publicado: (2020) -
Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic
por: Fragoulis, George E., et al.
Publicado: (2020) -
COVID-19: Pharmacology has kept the science ship running during the storm
por: Molimard, Mathieu, et al.
Publicado: (2021)